Suchergebnisse - "Bisbal, Otilia"

PubPharm (8)

1

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Suárez-García, I. | Alejos, B. | Hernando, V. | +111

2

Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain

enthalten in: AIDS research and human retroviruses | 2022

von Ruiz-Algueró, M. | Alejos, B. | García Yubero, C. | +110

3

Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

enthalten in: Frontiers in immunology | 2022

von Serrano-Villar, S. | López-Huertas, M. | Jiménez, D. | +12

CommentIn: Front Immunol. 2022 Apr 29;13:904689. - PMID 35572577

4

Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

enthalten in: The Journal of antimicrobial chemotherapy | 2021

von Montejano, R. | Dominguez-Dominguez, L. | de Miguel, R. | +19

5

Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure

enthalten in: The Journal of antimicrobial chemotherapy | 2021

von Jiménez de Ory, S. | Beltrán-Pavez, C. | Gutiérrez-López, M. | +112

6

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine : Week 96 results of ART-PRO pilot study

enthalten in: The Journal of antimicrobial chemotherapy | 2021

von Rial-Crestelo, D. | de Miguel, R. | Montejano, R. | +52

7

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine : 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

enthalten in: EBioMedicine | 2020

von De Miguel, R. | Rial-Crestelo, D. | Dominguez-Dominguez, L. | +20

CommentIn: EBioMedicine. 2020 Jun;56:102820. - PMID 32512519

8

Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2017

von Macías, J. | Mancebo, M. | Merino, D. | +29

1
[1]